Stroke is a leading cause of death and disability worldwide. Early recognition and prompt management can significantly improve patient outcomes. This article aims to provide a comprehensive guide for healthcare professionals to effectively recognize and manage strokes in their early stages.
The hallmark of early stroke recognition is the acronym FAST: Face drooping, Arm weakness, Speech difficulty, and Time to call emergency services. However, other signs such as sudden confusion, trouble seeing, difficulty walking, and severe headache with no known cause should also raise suspicion.
Upon suspicion of a stroke, a swift and thorough neurological examination is essential. Immediate imaging, preferably a non-contrast CT scan, is crucial to differentiate between ischemic and hemorrhagic stroke. Concurrently, stabilizing the patient's vitals and starting IV access should be prioritized.
Ischemic strokes, accounting for about 87% of all strokes, require immediate reperfusion therapy. Administering intravenous thrombolytic therapy within 4.5 hours of symptom onset can help salvage the ischemic penumbra. In selected patients, endovascular thrombectomy may be considered within 6-24 hours.
Hemorrhagic strokes necessitate rapid blood pressure control to prevent further bleeding. Neurosurgical consultation should be sought immediately for potential surgical interventions. Adequate hemostasis and reversal of anticoagulation are also critical.
Early recognition and appropriate management of stroke can drastically improve patient outcomes. By understanding the signs and symptoms of a stroke, initiating prompt diagnostic procedures, and employing effective treatment strategies, healthcare professionals can make a significant impact on the trajectory of this devastating disease.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation